MOLECULAR PARTNERS ADS/1
MOLECULAR PARTNERS ADS/1
Depository Receipt · US60853G1067 · MOLN · A3CSB5 (XNAS)
Overview
3,33 EUR
6,72 % 0,21 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 17:33

Current Prices from MOLECULAR PARTNERS ADS/1

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
MOLN
USD
06.06.2025 17:33
3,80 USD
3,56 USD
+6,72 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-0,45 % 0,09 % -11,13 % -21,94 % -38,38 % -11,51 % -80,76 %

Company Profile for MOLECULAR PARTNERS ADS/1 Depository Receipt

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Company Data

Name MOLECULAR PARTNERS ADS/1
Company Molecular Partners AG
Symbol MOLN
Website https://www.molecularpartners.com
Primary Exchange XNAS Frankfurt
WKN A3CSB5
ISIN US60853G1067
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Dr. Patrick Amstutz Ph.D.
Market Capitalization 147 Mio
Country Switzerland
Currency EUR
Employees 0,2 T
Address Wagistrasse 14, 8952 Schlieren
IPO Date 2021-06-16

Ticker Symbols

Name Symbol
Frankfurt 6ML0.F
NASDAQ MOLN

More Shares

Investors who MOLECULAR PARTNERS ADS/1 hold also have the following shares in their portfolio:
SYNTARA LTD.
SYNTARA LTD. Share
UNIDYNAMICFDS:EUR.N.A
UNIDYNAMICFDS:EUR.N.A Fund
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025